Two HIV patients with excess visceral abdominal fat responded differently to targeted therapies, revealing critical distinctions in fat distribution treatment. The first patient, with BMI 27 kg/m², achieved marked waist circumference reduction and improved lipid profiles using tesamorelin, a growth hormone-releasing hormone analog. The second patient initially received GLP-1 receptor agonists but required tesamorelin addition for effective visceral fat reduction despite higher overall BMI. This therapeutic differentiation matters because visceral adiposity in HIV patients represents a distinct metabolic phenotype that traditional weight-loss approaches may inadequately address. The finding challenges standard obesity management protocols that rely primarily on BMI categories. For the growing population of people living with HIV who develop metabolic complications despite viral suppression, these cases suggest that targeted visceral fat reduction may be more effective than generalized weight loss strategies. However, these are only two clinical cases, limiting broader applicability. The research underscores an emerging paradigm in precision medicine: matching therapeutic mechanisms to specific fat distribution patterns rather than applying uniform weight-management approaches across all metabolic presentations.